• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

    Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

  2. UPDATE: What 'Game of Thrones' can teach you about money

    UPDATE: What 'Game of Thrones' can teach you about money

  3. Oral OTEZLA® (apremilast) Demonstrated Clinically Meaningful and Sustained Improvements in Skin, Nail and Scalp of Adult Patients with Moderate to Severe Plaque Psoriasis

    Oral OTEZLA® (apremilast) Demonstrated Clinically Meaningful and Sustained Improvements in Skin, Nail and Scalp of Adult Patients with Moderate to Severe Plaque Psoriasis

  4. Credit Market Outlook: Bonds Priced for the Benign

    Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.

  5. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  6. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

  7. Do These Comeback Kids Have Long-Term Prospects?

    A closer look at a dozen resurgent U.S.-stock funds.

  8. Do These Comeback Kids Have Long-Term Prospects?

    A closer look at a dozen resurgent U.S.-stock funds.

  9. We See Major Upside Potential for InterMune's Shares

    Blockbuster sales and takeover potential create an attractive risk/reward tradeoff for this speculative biotech.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.